AcuCort AB announces that the trademark for the company’s medication Zeqmelit® has been registered for trademark protection in Switzerland.
The trademark protection is strategically important as the company enters its commercialization phase.
“It is very gratifying that we have now obtained trademark protection in Switzerland for our oral film Zeqmelit® with its associated areas of use. It is an important step towards commercialization in Switzerland,” says AcuCort’s CEO Jonas Jönmark.
The trademark protection for Zeqmelit® in Switzerland is valid for the next 10 years, after which the company must apply for an extension.
Zeqmelit® also has trademark protection in Europe (all European Union member states), Norway, the USA, the United Kingdom, Australia, China, India, and Japan.
Trademark protection is issued by the International Bureau of the World Intellectual Property Organization (WIPO).
For further information:
Jonas Jönmark, CEO AcuCort AB
Tel: +46 70 3655400
Email: jonas.jonmark@acucort.se
About AcuCort AB (publ)
AcuCort has developed and is commercializing Zeqmelit®, a new rapidly dissolving oral film placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for the treatment of patients with COVID-19 requiring supplemental oxygen therapy. Zeqmelit® is approved in Sweden, Denmark, Norway, and Finland. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market. Visit www.acucort.se for more information.